Betamethasone 0.1% dermatitis eczema cream/ointment (for reference, random packaging and delivery) Cream/OINTMENT
Betamethasone 0.1% dermatitis eczema cream/ointment (for reference, random packaging and delivery) Cream/OINTMENT
Betamethasone 0.1% dermatitis eczema cream/ointment (for reference, random packaging and delivery) Cream/OINTMENT
Betamethasone 0.1% dermatitis eczema cream/ointment (for reference, random packaging and delivery) Cream/OINTMENT
Betamethasone 0.1% dermatitis eczema cream/ointment (for reference, random packaging and delivery) Cream/OINTMENT
Betamethasone 0.1% dermatitis eczema cream/ointment (for reference, random packaging and delivery) Cream/OINTMENT
库存仅剩1 售罄

倍他米松Betamethasone 0.1% 皮炎湿疹乳膏/软膏 (图片仅供参考,随机包装发货)Cream/Ointment

£14.99 £14.99 售罄
- +
This is a prescription product provided through pharmacist assessment under an approved treatment plan.
Continue to Assessment
顾客还购买了
对于直邮到中国的订单,请访问我们的国际网站
Frequently Asked Questions
在使用倍他米松治疗湿疹或皮炎时,是否有哪些生活方式的建议可以帮助管理病情?
chevron-down
为配合您的治疗,请避免已知刺激物,定期使用无香型保湿剂,并保持皮肤湿润。 在症状爆发时,按医嘱使用倍他米松可帮助迅速缓解症状。 点击“开始咨询”,立即制定您的治疗方案。
在线上订购了倍他米松后的过程为何?
chevron-down
在您下单并完成咨询后,我们的团队会核查所有信息,以确保安全和适用性。如果倍他米松不适合您,我们的药剂师会为您提供替代方案。一旦获批,您的订单将被处理并寄出——您无需再做任何事情。
我如何通过 Ways Pharmacy 在线订购 0.1% 倍他米松乳膏?
chevron-down
要下单,只需开始咨询,选择 0.1% 倍他米松,并完成付款。我们的团队会审核您的病史,以确认该治疗是否适合您。如果它并非最佳选择,药师会为您推荐更安全的替代方案。一旦获批,我们将立即发货,无需额外步骤。
湿疹和皮炎的成因是什么?倍他米松适合我吗
chevron-down
湿疹和皮炎常由过敏、刺激物、压力或遗传因素引发,导致皮肤发炎和瘙痒。如果您正经历中度至重度的症状爆发,倍他米松可能适合您。点击「开始咨询」并填写快速评估表——我们的团队将审核您的信息,以确保该治疗适合您。
什么是 0.1% 倍氯米松乳膏?它用于治疗什么症状?
chevron-down
0.1% 倍氯米松乳膏是一种强效类固醇乳膏,用于缓解由湿疹和皮炎等皮肤疾病引起的红肿、瘙痒和炎症。它能快速平息皮肤发作,减轻不适感。若要开始治疗,请点击「开始咨询」,选择药物并在线完成支付。
Reviewed by
Chenyang Ma
Chenyang Ma
MPharm IP
Superintendent Pharmacist
Chenyang Ma is a GPhC-registered Superintendent Pharmacist at Ways Pharmacy in London. With a Master of Pharmacy (MPharm) from the University of Nottingham (2013), he combines strong commercial acumen and clinical expertise to drive patient-centric pharmacy services.
Reviewed Date
04 June 2025
Next Review
04 June 2026
Published On
04 June 2025
Last Updated
04 June 2025